These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 25046567)

  • 21. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
    Guo KY; Mei JZ; Yao KT
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):247-9. PubMed ID: 17425963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
    Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
    Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NKG2D Acts as a Co-Receptor for Natural Killer Cell-Mediated Anti-HIV-1 Antibody-Dependent Cellular Cytotoxicity.
    Parsons MS; Richard J; Lee WS; Vanderven H; Grant MD; Finzi A; Kent SJ
    AIDS Res Hum Retroviruses; 2016; 32(10-11):1089-1096. PubMed ID: 27487965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
    Mei JZ; Guo KY; Wei HM; Song CY
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway.
    Wu HY; Li KX; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Huang YX
    Int Immunopharmacol; 2022 Mar; 104():108497. PubMed ID: 34999394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential survival of γδT cells, αβT cells and NK cells upon engagement of NKG2D by NKG2DL-expressing leukemic cells.
    Poggi A; Zancolli M; Boero S; Catellani S; Musso A; Zocchi MR
    Int J Cancer; 2011 Jul; 129(2):387-96. PubMed ID: 20853320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
    Inagaki A; Ishida T; Yano H; Ishii T; Kusumoto S; Ito A; Ri M; Mori F; Ding J; Komatsu H; Iida S; Ueda R
    Int J Cancer; 2009 Jul; 125(1):212-21. PubMed ID: 19358282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
    Cheney CM; Stephens DM; Mo X; Rafiq S; Butchar J; Flynn JM; Jones JA; Maddocks K; O'Reilly A; Ramachandran A; Tridandapani S; Muthusamy N; Byrd JC
    MAbs; 2014; 6(3):749-55. PubMed ID: 24594909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NKG2D functions as an activating receptor on natural killer cells in the common marmoset (Callithrix jacchus).
    Watanabe M; Kudo Y; Kawano M; Nakayama M; Nakamura K; Kameda M; Ebara M; Sato T; Nakamura M; Omine K; Kametani Y; Suzuki R; Ogasawara K
    Int Immunol; 2014 Nov; 26(11):597-606. PubMed ID: 24860119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
    Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
    Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
    Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
    Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas.
    Hagelstein I; Lutz MS; Schmidt M; Heitmann JS; Malenke E; Zhou Y; Clar KL; Kopp HG; Jung G; Salih HR; Märklin M; Hinterleitner C
    Front Immunol; 2021; 12():653081. PubMed ID: 33936075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NK cell-mediated anti-leukemia cytotoxicity is enhanced using a NKG2D ligand MICA and anti-CD20 scfv chimeric protein.
    Zou Y; Luo W; Guo J; Luo Q; Deng M; Lu Z; Fang Y; Zhang CC
    Eur J Immunol; 2018 Oct; 48(10):1750-1763. PubMed ID: 30063799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity.
    Satwani P; Bavishi S; Saha A; Zhao F; Ayello J; van de Ven C; Chu Y; Cairo MS
    Cytotherapy; 2014 Oct; 16(10):1431-40. PubMed ID: 24856896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells.
    Falco M; Marcenaro E; Romeo E; Bellora F; Marras D; Vély F; Ferracci G; Moretta L; Moretta A; Bottino C
    Eur J Immunol; 2004 Jun; 34(6):1663-72. PubMed ID: 15162436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
    Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
    Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer.
    Mimura K; Kamiya T; Shiraishi K; Kua LF; Shabbir A; So J; Yong WP; Suzuki Y; Yoshimoto Y; Nakano T; Fujii H; Campana D; Kono K
    Int J Cancer; 2014 Sep; 135(6):1390-8. PubMed ID: 24615495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor.
    Schirrmann T; Pecher G
    Leuk Res; 2005 Mar; 29(3):301-6. PubMed ID: 15661266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.